Replies to post #171495 on Biotech Values

[gdollasign]

That the market expects ABBV/ENTA to get less than 38% of the GT1 market is clear

I would think that we may be underestimating the potential market share once pricing has evolved. The numbers are the numbers and the numbers are liabilities to insurance companies. Given neck and neck trial results, there seems to be a possibility that ENTA gathers 62% and GILD enjoys 38%. Just thinking.